Protocol Ledger

NCT05633602 · Phase III · ACTIVE NOT RECRUITING

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Interventional Phase III clinical trial protocol NCT05633602 sponsored by SWOG Cancer Research Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-14 Enrollment: 838 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05633602
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)838 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05633602
Protocol FieldVerified Registry Value
NCT IdentifierNCT05633602
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment838 participants (ACTUAL)
Registered Start Date2023-03-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI